What's Happening?
A new in-situ dual-lighting system (ISDLS) has been developed to improve the detection of HER2 nucleic acid and protein in cancer diagnosis. This system combines molecular beacon-based loop-mediated isothermal amplification (LAMP) and tyramide signal
amplification (TSA)-based immunohistochemistry (IHC) to provide accurate and sensitive detection in a single pathological section. The study demonstrated that ISDLS could achieve a 100% detection rate for clinical IHC ≥ 1+ and fluorescence in situ hybridization (FISH) positive sections, and a 77.8% detection rate for FISH negative sections. This method allows for the spatial distribution of amplified signals, enabling multidimensional analysis of diseases.
Why It's Important?
The development of ISDLS is significant as it addresses the limitations of current HER2 detection methods, which often require confirmation through multiple tests. By providing a more accurate and sensitive detection method, ISDLS could lead to better-targeted therapies for patients with HER2-positive cancers, including those with low HER2 expression who may still benefit from targeted treatments. This advancement could improve patient outcomes and streamline diagnostic processes, reducing the need for multiple tests and potentially lowering healthcare costs.
